Recombinant human soluble extracellular Flt-1 (D1-D5)
Kreuzreaktivität
Maus
Kreuzreaktivität (Details)
The antibody cross-reacts with mouse Flt-1 (e.g. natural occurring soluble mouse Flt-1) in Western analysis.
Produktmerkmale
Chromosomal location: 13q12 The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular Flt-1 (D1-D5) as the immunizing antigen. The antibody can be used for ELISA experiments, Western blotting, immunofluorescence, and immunoprecipitation. It will recognize recombinant and naturally occurring form of human VEGFR-1/Flt-1. The antibody cross-reacts with mouse Flt-1 (e.g. natural occurring soluble mouse Flt-1) in Western analysis.
Aufreinigung
Mouse IgG1 antibody (#EWI) from hybridomas was purified from cell culture supernatant by Protein G chromatography.
Immunogen
Recombinant human soluble extracellular Flt-1 (D1-D5)
ELISA: Use at 1-10 μg/mL, Western blotting: Use 2-5 μg/mL, Immunoprecipitation: Use 2-10 μg/mL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
Buffer
PBS, BSA (50x), 0.02 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Centrifuge vial prior to opening.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
Vascular endothelial growth factor receptor-1, FLT1, VEGF receptor 1,Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.